Veracyte, Inc. operates as a diagnostics company in the United States and internationally. The company offers Afirma Genomic Sequencing Classifier for cancerous thyroid nodules; Decipher Prostate Biopsy and Radical Prostatectomy for prostate cancer diagnosis; Prosigna Breast Cancer Assay for breast cancer diagnosis; Percepta Nasal Swab Test for lung cancer diagnosis; and Envisia Genomic Classifier for diagnosing interstitial lung disease, including idiopathic pulmonary fibrosis. It is also developing Envisia Classifier, the nCounter analysis system; and LymphMark for lymphoma subtyping test. The company was formerly known as Calderome, Inc. and changed its name to Veracyte, Inc. in March 2008. Veracyte, Inc. was incorporated in 2006 and is headquartered in South San Francisco, California.
| 23.72 | |
| 24.31 | |
| - | |
| 24.675 | |
| 23.58 | |
| 18.61-29.35 | |
| 1 813 M | |
| 76 448 K | |
| 375 M | |
| -0.02 | |
| 1.644 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
SOUTH SAN FRANCISCO, Calif., July 17, 2024--(BUSINESS WIRE)--Veracyte, Inc. (Nasdaq: VCYT) announced today that it will release financial results for the second quarter of 2024 after the close of mark...
Veracyte VCYT shares ended the last trading session 13.2% higher at $25.56. The jump came on an impressive volume with a higher-than-average number of shares changing hands in the session. This compar...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
